← Back to Search

Androgen Biosynthesis Inhibitor

Abiraterone acetate with Prednisone for Prostate Cancer

N/A
Waitlist Available
Led By Richard Lee, MD, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This study is evaluating whether a drug that has been used in other studies can be used in combination with a drug that has been used in other studies to treat prostate cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of AR signaling in CTCs and correlation with response
Secondary outcome measures
Change in number and proliferative fraction of CTCs with abiraterone treatment

Trial Design

1Treatment groups
Experimental Treatment
Group I: Abiraterone acetate with PrednisoneExperimental Treatment2 Interventions
1000 mg Abiraterone daily by mouth, 4 x 250 mg tablets Prednisone administered as 5 mg orally twice a day
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abiraterone
FDA approved
Prednisone
FDA approved

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,925 Previous Clinical Trials
13,197,864 Total Patients Enrolled
34 Trials studying Prostate Cancer
2,938 Patients Enrolled for Prostate Cancer
Richard Lee, MD, PhDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
500 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Abiraterone Acetate for Castrate Resistant Prostate Cancer
Richard J. Lee, MD 2013. "Abiraterone Acetate for Castrate Resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01961843.
All > Abiraterone Acetate
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top